Hedy Kindler to Immunotherapy
This is a "connection" page, showing publications Hedy Kindler has written about Immunotherapy.
Connection Strength
0.858
-
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 Nov; 20(11):1615-1625.
Score: 0.602
-
Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Oncotarget. 2025 Jun 10; 16:427-442.
Score: 0.150
-
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
Score: 0.044
-
Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct; 1(4):313-26.
Score: 0.027
-
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365.
Score: 0.027
-
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002 Feb; 29(1):82-96.
Score: 0.007